Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
TB-500 itself remains an investigational compound, meaning it has not been approved as a standalone drug by the FDA
Neuropathic Symptoms PainDetect
QD community oral or SC MOTS-c Daily SC, often 5 days on / 2 off AOD-9604 Daily SC Attribute Max studied dose SLU-PP-332 50 mg/kg BID (mouse, 28 days) MOTS-c 5-15 mg/kg (mouse) AOD-9604 1-5 mg/day in human Phase 2 Attribute Peak efficacy signal SLU-PP-332 ~25-30% fat-mass reduction in DIO mice over 28 days MOTS-c Improved insulin sensitivity in aged mice AOD-9604 Modest fat-loss signal in human Phase 2
In addition, the development of immunopeptidome analysis should provide successful targets and open the way to a new generation of senolytic treatments
